Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04209465 · MORE INFO

Limitations, agreements, and source contact

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. · Source last updated 2025-04-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Study terminated early. Phase 2 was not conducted. Limited data collection was performed for this study.
point Of Contact
email
ClinicalTrials@bdtx.com
organization
Black Diamond Therapeutics, Inc.
phone
617-401-8444
title
Medical Monitor
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Study terminated early. Phase 2 was not conducted. Limited data collection was performed for this study.
point Of Contact
email
ClinicalTrials@bdtx.com
organization
Black Diamond Therapeutics, Inc.
phone
617-401-8444
title
Medical Monitor

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice